Jennifer Anne Jenks

Jennifer Anne Jenks

Auto-generated profile, based on publicly available information

Jennifer Anne Jenks

Duke Human Vaccine Institute, Duke University Medical Center

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CNCody S. Nelson
Cody S. Nelson
THTori Huffman
Tori Huffman
JJJennifer A. Jenks
Jennifer A. Jenks
EREduardo Cisneros de la Rosa
Eduardo Cisneros de la Rosa
GXGuanhua Xie
Guanhua Xie
SPSallie Permar
Sallie Permar
Significance: The CDC estimates that every hour, a child is born in the United States with permanent neurologic disability resulting from human cytomegalovirus (HCMV) infection—more than is caused by Down syndrome, fetal alcohol syndrome, and neural tube defects combined. A maternal vaccine to block transmission of HCMV to the developing fetus is a necessary intervention to prevent these adverse outcomes. The gB/MF59 vaccine is the most successful tested clinically to date, achieving 50% reduction in HCMV acquisition. This manuscript establishes the function and epitope specificity of the humoral response stimulated by this vaccine that may explain the partial vaccine efficacy. Understanding the mechanism of gB/MF59-elicited protective immune responses will guide rational design and evaluation of the next generation of HCMV vaccines.

1 January 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
RHRamona A. Hoh
Ramona A. Hoh
SJShilpa A. Joshi
Shilpa A. Joshi
YLYi Liu
Yi Liu
CWChen Wang
Chen Wang
KRKrishna M. Roskin
Krishna M. Roskin
SBScott Boyd
Scott Boyd

1 January 2012 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
TKTakahiro Kanai
Takahiro Kanai
JJJennifer Jenks
Jennifer Jenks
Kari NadeauKari Nadeau
Kari Nadeau
The signal transducer and activator of transcription (STAT) 5b is a universal transcription factor that plays key biological roles in allergic diseases, immunodeficiencies, autoimmunities, cancers, hematological diseases, growth disorders, and lung diseases. The identification of distinct pathological manifestations of STAT5b deficiency in humans has highlighted the critical role of the STAT5b pathway. Proper gene transcription at IL-2R α, FOXP3, Bcl-2, and growth hormone (GH) associated loci are thought to be associated with normal STAT5b transcriptional activity. These genes are thought to play important roles in allergy/autoimmunity, immunodeficiency, cancer/anemia, and growth, respectively. The STAT5A and STAT5B genes are collocated on 17q11. Although these two monomeric proteins exhibit peptide sequence similarities of >90%, it is known through observations of STAT5b deficient subjects that STAT5a and STAT5b are not fully redundant in humans. Patients with STAT5b deficiency have decreased numbers of regulatory CD4+CD25high T cell (Treg) despite their STAT5a levels being normal. Prior studies on STAT5b deficient subjects have revealed immunological aberrations associated with the following disease phenotype: modest lymphopenia and decreased populations of Treg, γ−δ T cells, and natural killer (NK) cells. Most subjects with STAT5b deficiency show severe eczema, and autoimmune disease (juvenile idiopathic arthritis, autoimmune thyroiditis, idiopathic thrombocytic purpura) which are thought to be associated with Treg dysfunction. We will review the likely pathophysiological mechanisms associated with STAT5b deficiency.

30 April 2014 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
LPLaurence Pellerin
Laurence Pellerin
JJJennifer A. Jenks
Jennifer A. Jenks
PBPhilippe Bégin
Philippe Bégin
RBRosa Bacchetta
Rosa Bacchetta
Kari NadeauKari Nadeau
Kari Nadeau

30 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TKTakahiro Kanai
Takahiro Kanai
SSScott Seki
Scott Seki
JJJennifer A. Jenks
Jennifer A. Jenks
AKArunima Kohli
Arunima Kohli
TKTrupti Kawli
Trupti Kawli
KNKari C. Nadeau
Kari C. Nadeau
Signal transducer and activator of transcription (STAT) comprises a family of universal transcription factors that help cells sense and respond to environmental signals. STAT5 refers to two highly related proteins, STAT5A and STAT5B, with critical function: their complete deficiency is lethal in mice; in humans, STAT5B deficiency alone leads to endocrine and immunological problems, while STAT5A deficiency has not been reported. STAT5A and STAT5B show peptide sequence similarities greater than 90%, but subtle structural differences suggest possible non-redundant roles in gene regulation. However, these roles remain unclear in humans. We applied chromatin immunoprecipitation followed by DNA sequencing using human CD4+ T cells to detect candidate genes regulated by STAT5A and/or STAT5B, and quantitative-PCR in STAT5A or STAT5B knock-down (KD) human CD4+ T cells to validate the findings. Our data show STAT5A and STAT5B play redundant roles in cell proliferation and apoptosis via SGK1 interaction. Interestingly, we found a novel, unique role for STAT5A in binding to genes involved in neural development and function (NDRG1, DNAJC6, and SSH2), while STAT5B appears to play a distinct role in T cell development and function via DOCK8, SNX9, FOXP3 and IL2RA binding. Our results also suggest that one or more co-activators for STAT5A and/or STAT5B may play important roles in establishing different binding abilities and gene regulation behaviors. The new identification of these genes regulated by STAT5A and/or STAT5B has major implications for understanding the pathophysiology of cancer progression, neural disorders, and immune abnormalities.

7 February 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
XHXintao Hu
Xintao Hu
KKKrithika P Karthigeyan
Krithika P Karthigeyan
SHSavannah Herbek
Savannah Herbek
SVSarah M Valencia
Sarah M Valencia
JJJennifer A Jenks
Jennifer A Jenks
SPSallie Permar
Sallie Permar
Background: MF59-adjuvanted gB subunit (gB/MF59) vaccine demonstrated approximately 50% efficacy against human cytomegalovirus (HCMV) acquisition in multiple clinical trials, suggesting that efforts to improve this vaccine design might yield a vaccine suitable for licensure. Methods: A messenger RNA (mRNA)–based vaccine candidate encoding HCMV gB and pentameric complex (PC), mRNA-1647, is currently in late-stage efficacy trials. However, its immunogenicity has not been compared to the partially effective gB/MF59 vaccine. We assessed neutralizing and Fc-mediated immunoglobulin G (IgG) effector antibody responses induced by mRNA-1647 in both HCMV-seropositive and -seronegative vaccinees from a first-in-human clinical trial through 1 year following third vaccination using a systems serology approach. Furthermore, we compared peak anti-gB antibody responses in seronegative mRNA-1647 vaccinees to that of seronegative gB/MF59 vaccine recipients. Results: mRNA-1647 vaccination elicited and boosted HCMV-specific IgG responses in seronegative and seropositive vaccinees, respectively, including neutralizing and Fc-mediated effector antibody responses. gB-specific IgG responses were lower than PC-specific IgG responses. gB-specific IgG and antibody-dependent cellular phagocytosis responses were lower than those elicited by gB/MF59. However, mRNA-1647 elicited higher neutralization and antibody-dependent cellular cytotoxicity (ADCC) responses. Conclusions: Overall, mRNA-1647 vaccination induced polyfunctional and durable HCMV-specific antibody responses, with lower gB-specific IgG responses but higher neutralization and ADCC responses compared to the gB/MF59 vaccine. Clinical Trials Registration: NCT03382405 (mRNA-1647) and NCT00133497 (gB/MF59).